| 000 | 01605 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516131828.0 | ||
| 264 | 0 | _c20130815 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1573-6903 | ||
| 024 | 7 |
_a10.1007/s11064-012-0965-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRibeiro, Renata Pietsch | |
| 245 | 0 | 0 |
_aProbucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bNeurochemical research _cMar 2013 |
||
| 300 |
_a660-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCatalase _xmetabolism |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 |
_aDopaminergic Neurons _xdrug effects |
| 650 | 0 | 4 |
_aLipid Peroxidation _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aProbucol _xtherapeutic use |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aMoreira, Eduardo Luiz Gasnhar | |
| 700 | 1 | _aSantos, Danúbia Bonfanti | |
| 700 | 1 | _aColle, Dirleise | |
| 700 | 1 | _aDos Santos, Alessandra Antunes | |
| 700 | 1 | _aPeres, Kaite Cristiane | |
| 700 | 1 | _aFigueiredo, Claudia Pinto | |
| 700 | 1 | _aFarina, Marcelo | |
| 773 | 0 |
_tNeurochemical research _gvol. 38 _gno. 3 _gp. 660-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11064-012-0965-0 _zAvailable from publisher's website |
| 999 |
_c22433721 _d22433721 |
||